| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Convalescent plasma in outpatients with COVID-19
|
Focosi, Daniele
|
|
|
10 |
3 |
p. 226-228
|
article
|
| 2 |
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations
|
Aliberti, Stefano
|
|
|
10 |
3 |
p. 298-306
|
article
|
| 3 |
Do vaccines protect from long COVID?
|
Venkatesan, Priya
|
|
|
10 |
3 |
p. e30
|
article
|
| 4 |
Eat or heat: fuel poverty and childhood respiratory health
|
Barrett, Cassandra
|
|
|
10 |
3 |
p. 229
|
article
|
| 5 |
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
|
Sutharsan, Sivagurunathan
|
|
|
10 |
3 |
p. 267-277
|
article
|
| 6 |
Extracorporeal haemoadsorption: does the evidence support its routine use in critical care?
|
Supady, Alexander
|
|
|
10 |
3 |
p. 307-312
|
article
|
| 7 |
Future pandemics: failing to prepare means preparing to fail
|
The Lancet Respiratory Medicine,
|
|
|
10 |
3 |
p. 221-222
|
article
|
| 8 |
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
|
Alemany, Andrea
|
|
|
10 |
3 |
p. 278-288
|
article
|
| 9 |
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis
|
Dahmer, Mary K
|
|
|
10 |
3 |
p. 289-297
|
article
|
| 10 |
It is time to include real-world effectiveness data on medicinal product labels
|
Dal-Ré, Rafael
|
|
|
10 |
3 |
p. e28-e29
|
article
|
| 11 |
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
|
Temesgen, Zelalem
|
|
|
10 |
3 |
p. 237-246
|
article
|
| 12 |
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
|
Fisher, Benjamin A
|
|
|
10 |
3 |
p. 255-266
|
article
|
| 13 |
Respiratory health and critical care concerns in Afghanistan
|
Shah, Jaffer
|
|
|
10 |
3 |
p. 229-231
|
article
|
| 14 |
Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial
|
Karakas, Mahir
|
|
|
10 |
3 |
p. 247-254
|
article
|
| 15 |
Stimulating severe COVID-19: the potential role of GM-CSF antagonism
|
Leavis, Helen L
|
|
|
10 |
3 |
p. 223-224
|
article
|
| 16 |
The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock
|
Tehrani, Behnam N
|
|
|
10 |
3 |
p. 224-226
|
article
|
| 17 |
The ongoing battle to address respiratory health in people experiencing homelessness
|
Burki, Talha Khan
|
|
|
10 |
3 |
p. 233-236
|
article
|
| 18 |
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis
|
de Brabander, Justin
|
|
|
10 |
3 |
p. e25-e26
|
article
|
| 19 |
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply
|
Gangneux, Jean-Pierre
|
|
|
10 |
3 |
p. e27
|
article
|
| 20 |
Vaccination in the world's top athletes
|
Burki, Talha Khan
|
|
|
10 |
3 |
p. e33
|
article
|
| 21 |
Volcanic eruption in Tonga and effects on respiratory health
|
Burki, Talha Khan
|
|
|
10 |
3 |
p. e31-e32
|
article
|
| 22 |
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?
|
Lewer, Dan
|
|
|
10 |
3 |
p. 231-233
|
article
|
Journal description